跳至主要内容
临床试验/IRCT20200406046965N2
IRCT20200406046965N2招募中2 期

Evaluation of the effect of Thymus kotschyanus Boiss. & Hohen. in improving ulcerative colitis symptoms

Mashhad University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
13 years 至 65 years(—)
性别
All

入选标准

  • Patients who were diagnosed by ulcerative colitis and not been hospitalized during this clinical trial
  • Patients must be between 13 and 65 years' old
  • The Simple Clinical Colitis Activity Index (SCCAI) score must be higher than 5 and less than 13
  • Patients must have taken mesalazine with fixed dose since at least 1 month ago and not exceed more than 4.5 grams mesalazine in a day
  • If patients have administered topical mesalazine it should be used at least for 2 weeks with a fixed dose and not exceed more than 4 grams in a day
  • Patients shouldn’t have taken another anti-inflammatory or immunomodulatory medicine except mesalazine
  • Hemoglobin must be higher than 10
  • No concurrent disease such as diabetes, cardiovascular disease, kidney disease, liver disease, thyroid disease, bile disease
  • No concurrent leukopenia, thrombocytopenia or other blood coagulation disorders
  • No concurrent sepsis or any active infection
  • No pregnancy or breast feeding
  • No taking any anti-coagulant medicine
  • No history for epilepsy or convulsions

排除标准

  • Acute severe ulcerative colitis requiring hospital admission (SCCAI >13); inactive disease (SCCAI < 3).
  • A history of sensitivity to Thymus kotschyanus or its preparations.
  • A history of diabetes, cardiovascular diseases, kidney disease, liver diseases, thyroid disease, bile disease and leukopenia, thrombocytopenia.
  • Hemoglobin less than 10.
  • Reluctance to continue this trial.

研究者

相似试验